Webinar 2: When Innovation Rewrites the Pathway
Oct 16, 2026
From Canadian Experience to Phase 2 Readiness How can Phase 2 RDDS help Canada anticipate the pathway consequences of new rare and precision therapies - so that screening, diagnosis, eligibility, expertise, delivery, patient choice, monitoring and learning do not have to be rebuilt after each access decision?
Speakers: Kim Steele, Cystic Fibrosis Canada
Susi Vander Wyk, Cure SMA Canada
Audrey Belouin, Canadian Association of Pompe (TBC)
Read More
CORD Fall Conference 2026
Nov 12-13, 2026
/
Halifax
Read More
